Inpharmus
Focus: Inpharmus is a Turkish biotechnology company founded in 2013 that operates primarily as a commercializer of established small-molecule and biologic drugs across multiple therapeutic areas. The company generates 71% of revenue from VASCEPA (icosapent ethyl), a peak-stage cardiovascular therapeutic.
Profile data last refreshed 21h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Inpharmus
AI assessmentNot HiringNo open roles listed right now. Follow Inpharmus to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Inpharmus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthWatch
Pipeline
Early-stage
0 total
LOE Risk
2 imminent
DYLOJECT
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$764M Part DStable
Peak6.7yr
Flagship revenue driver (71% of company revenue) with 9-year patent protection remaining; core commercial franchise.
Help build intelligence for Inpharmus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.